62 results about "Emotional disorder" patented technology

A system and method for diagnosing mental or emotional disorders is disclosed. An affective BCI component is incorporated into a closed loop, symptom—responsive psychiatric DBS system. A series of input data related to a brain of the patient is acquired while the patient performs a battery of behavioral tasks. From the patient's performance on the task battery, the system identifies what is abnormal for that individual patient in terms of functional domains. Patient-specific behavioral measurements are then linked to patterns of activation and de-activation across different brain regions, identifying specific structures that are the source of the patient's individual impairment.

The invention relates to methods and products for treating emotional disorders such as stress induced emotional disorders, as well as related assays and kits. Methods include administering to a subject an effective amount of an agent for targeting the Rac1, Cdk5, p35, PAK-1 pathway to treat the emotional disorder. The agent for targeting the Rac1, Cdk5, p35, PAK-1 pathway may be, for instance a Rac-1 inhibitor, a Cdk5 inhibitor, a PAK-1 activator, or p35 mobilizing agent.

The present invention provides a group of tobacco alkaloids, tobacco extract, Yerbamaté extract, and an extract of chewing gum and lozenges which are modulators of monoamine oxidase (MAO) activity (i.e., compounds and substances which inhibit MAO enzyme and prevent its biological activity). The MAO inhibitors of the present invention can cause an increase in the level of norepinephrine, dopamine, and serotonin in the brain and other tissues, and thus can cause a wide variety of pharmacological effects mediated by their effects on these compounds. The MAO inhibitors of the present invention are useful for a variety of therapeutic applications, such as the treatment of depression, disorders of attention and focus, mood and emotional disorders, Parkinson's disease, extrapyramidal disorders, hypertension, substance abuse, smoking substitution, anti-depression therapy, eating disorders, withdrawal syndromes, and the cessation of smoking.

The invention belongs to the technical field of traditional Chinese medicines, and particularly discloses a traditional Chinese medicine composition for treating depression and emotional disorder diseases. The composition is prepared from the following components in parts by weight: 12-20 parts of Chinese thorowax roots, 12-20 parts of Chinese angelica, 12-20 parts of poria cocos, 12-20 parts of debark peony roots, 12-20 parts of largehead atractylodes rhizomes, 3-8 parts of raw ginger, 3-8 parts of mint, 3-8 parts of prepared liquorice and 2-6 parts of donkey-hide gelatin. The invention alsodiscloses a preparation method of the traditional Chinese medicine composition. The Chinese angelica, the debark peony roots and the Chinese thorowax roots have the effects of stabilizing the mood ofa patient and relieving depression, and have the characteristics of less side effects and no dependence compared with western medicines. The traditional Chinese medicine components have synergistic effect, and the composition is mild in medicinal property, gives consideration to deficiency and excess, has high safety, and improves the curative effect of depression and the compliance of patients.

The invention provides a method for inhibiting melatonin secretion by using a light source. According to the method, a lighting device is specially designed to emit lighting light having a specific wavelength within the wavelength range of 581nm and 590nm, and various experimental data have proved that the lighting light can be used to serve as a melatonin secretion inhibitor. Therefore, the experimental data have proved that the lighting device of the invention is suitable for being used for light therapy for winter depression, thereby treating the seasonal affective disorder (namely the winter depression) by inhibiting the melatonin secretion. Briefly speaking, after a patient suffering from the winter depression receives a treatment course of the light therapy with the lighting light with the wavelength range of 581-590nm, the symptoms of the winter depression, including somnolence, emotional disorder and the like, of the patient suffering from the winter depression can be cured finally due to the fact that the patient has a good mental state and a stable emotional state.

The present invention provides compounds represented by general formula (I), wherein the substituents are as defined in the application. The compounds are useful in the treatment of affective disorders including depression, anxiety disorders including generalized anxiety disorder, panic disorder and obsessive-compulsive disorder.

The present invention provides a group of tobacco alkaloids, tobacco extract, Yerbamaté extract, and an extract of chewing gum and lozenges which are modulators of monoamine oxidase (MAO) activity (i.e., compounds and substances which inhibit MAO enzyme and prevent its biological activity). The MAO inhibitors of the present invention can cause an increase in the level of norepinephrine, dopamine, and serotonin in the brain and other tissues, and thus can cause a wide variety of pharmacological effects mediated by their effects on these compounds. The MAO inhibitors of the present invention are useful for a variety of therapeutic applications, such as the treatment of depression, disorders of attention and focus, mood and emotional disorders, Parkinson's disease, extrapyramidal disorders, hypertension, substance abuse, smoking substitution, anti-depression therapy, eating disorders, withdrawal syndromes, and the cessation of smoking.

The invention relates to a medicament for treating arrhythmia, in particular to a Chinese medicine composition which is prepared by using plant Chinese herbal medicines as raw materials and is used for treating arrhythmia. The Chinese medicine composition is characterized by comprising the following raw medicines for preparing effective components of the composite by weight: 10-18g of codonopsis pilosula, 5-15g of astragalus mongholicus, 5-15g of angelica sinensis, 5-15g of rehmanniae praeparat, 5-15g of salvia miltiorrhiza bunge, 4-12g of safflower, 4-12g of Chinese yam, 4-12g of poria cocos, 3-8g of platycladi seed, 3-8g of spina date seed, 3-8g of Chinese magnoliavine fruit and 3-8g of radix glycyrrhizae preparata. The matching of the medicines of the invention brings out the best in each other; the Chinese medicine composition has the effects of tonifying spleen and qi, harmonizing the stomach, nourishing the blood, tonifying lung, consolidating superficies, nourishing heart, calming the nerves, supplementing and activating blood, nourishing kidney, promoting the production of body fluid, tonifying qi, restoring pulse, and the like; through the synergy of the medicament effects, the Chinese medicine composition provided by the invention can treat both principal and secondary aspects of diseases and has no side effect; and the invention has obvious curative effect mainly on arrhythmia caused by yin and yang asthenic disease of qi blood of internal organs, internal injury due to emotional disorder, heart malnutrition due to interaction of qi stagnation and blood stasis and heart vessel unsmoothness.

The invention provides a multi-modal user emotion analysis method based on a knowledge graph. The method comprises the steps of acquiring an emotion analysis service request of a user is received or authorization of social network data of the monitored user applied to emotion analysis service; acquiring user social network data, establishing a user graph model based on the user social network data, the user graph model comprises a data graph DGraph, an information graph IGraph and a knowledge graph KGraph, and storing DDIK, IDIK and KDIK resources respectively; extracting an interactive relationship tuple Inter (user) of the user and other people from the user graph model, substituting the Inter (user) into the function for calculation, and analyzing the emotional tendency of the user according to a calculation result; and sending the emotion tendency analysis result to the corresponding user. According to the method, the emotional tendency of the user can be analyzed based on massivesocial network data under the condition that the user does not perceive, so that the user is helped to know the emotional tendency situation in time, and emotional disorders are prevented.

The invention discloses a Chinese medicine composition for treating chronic ulcerative colitis. The Chinese medicine composition comprises the Chinese medicinal herbs: flabelate maiden-hair herb, root of smalleaf desmodium, silverweed cinquefoil root, emperor woodbetony root, sword bean, syringa pinnatifolia, gorse, hairy waxmyrtle bark, tetracera scandens and chinese granesbill. Through clinical tests in our hospital, the traditional Chinese medicine considers that the chronic ulcerative colitis belongs to categories of 'lingering dysentery, diarrhoea, hematochezia and spouting bleeding from anus', and is caused by externally infection of dampness pathogen, improper diet, emotional disorder and insufficiency of natural endowment. Spleen and kidney deficiencies are symptoms, dampness, cold, fever, qi stagnation, blood stasis and the like are root causes. Through clinical tests in our hospital, the cure rate and the total effective rate of a treatment group are respectively 54.3 percent and 97.8 percent, and remarkably superior to the cure rate and the total effective rate of a control group,namely respectively 23.9 percent and 73.9 percent; the Chinese medicine composition is small in side effects, low in recurrence rate, and worthy of clinical popularization and application.

The invention relates to methods and products for treating emotional disorders such as stress induced emotional disorders, as well as related assays and kits. Methods include administering to a subject an effective amount of an agent for targeting the Rac1, Cdk5, p35, PAK-1 pathway to treat the emotional disorder. The agent for targeting the Rac1, Cdk5, p35, PAK-1 pathway may be, for instance, a Rac-1 inhibitor, a Cdk5 inhibitor, a PAK-1 activator, or p35 mobilizing agent.

The invention discloses an olanzapine-fluoxetine compound capsule preparation and a preparation method thereof, which are used for the drug treatment of bipolar affective disorder. The compound preparation contains two different pellets, which are respectively enteric-coated olanzapine-containing Flat sustained-release pellets and gastric-soluble fluoxetine-containing sustained-release pellets; the olanzapine-fluoxetine compound capsule preparation of the present invention is combined according to the different in vivo pharmacokinetic laws of olanzapine and fluoxetine Two types of pellets with different ratios and different release parts complete the preparation of products of different specifications; achieve rapid onset of effect, synergistic effect, and reduce the number of times of taking medicine.